Business Wire Feed

Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients

April 27th, 2026|

For Trade and Medical Media Only The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90 Study showed favourable benefit for toxicity-related discontinuations and drug-drug interactions (DDIs) more...

vVARDIS Announces Investment from Apollo —Achieves Unicorn Status

April 27th, 2026|

Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesionZUG, Switzerland--(BUSINESS WIRE)--vVARDIS Holding AG (“vVARDIS”), more...

OmniAb to Participate in Three Upcoming Investor Conferences

April 24th, 2026|

EMERYVILLE, Calif.--(BUSINESS WIRE)--$OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in three investor conferences over the coming weeks. H.C. Wainwright 2nd Annual Royalty Company Virtual Conference, May 6. Management will participate more...

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.